Home
News
Create
Screeners
Insights
Amanta Healthcare
108.
07
+2.26
(+2.14%)
Market Cap
₹419.63 Cr
PE Ratio
26.74
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+2.14%
1M
+4.97%
6M
-20.73%
1Y
-23.76%
5Y
-23.76%
View Company Insights
Latest news about Amanta Healthcare
Amanta Healthcare Schedules Analysts and Institutional Investors Meeting for April 2026
2 days ago
Amanta Healthcare Limited has scheduled an analysts and institutional investors meeting for April 7, 2026, at Kheda, Gujarat, featuring in-person group discussions and site visit. The company has assured compliance with regulatory requirements, confirming no price sensitive information will be shared during the meeting.
Amanta Healthcare Limited Files Annual SEBI SAST Disclosures for FY 2025-26
2 days ago
Amanta Healthcare Promoter Increases Stake Through Open Market Purchase of 28,800 Shares
3 days ago
Bandhan Mutual Fund Files SEBI Disclosure After Crossing 5% Stake in Amanta Healthcare
7 days ago
Amanta Healthcare Reports Insider Purchase of 15,675 Equity Shares by Director's Relative
9 days ago
More news about Amanta Healthcare
27
Feb 26
Amanta Healthcare Promoter Increases Stake Through Open Market Purchase
Amanta Healthcare Limited disclosed that promoter Bhavesh Girishbhai Patel acquired 48,151 equity shares worth ₹50.20 lakh through open market purchases on February 26-27, 2026. The transaction increased his shareholding from 62,49,593 shares (16.10%) to 62,97,744 shares (16.22%). The disclosure was made under SEBI Insider Trading Regulations with shares purchased through NSE market transactions.
16
Feb 26
Amanta Healthcare Hosts Maiden Earnings Call, Outlines ₹150 Crore Revenue Expansion Plan
Amanta Healthcare held its first earnings conference call following Q3FY26 results, with management detailing major expansion plans including doubling SteriPort capacity and SVP line enhancement. The company projects ₹150 crore incremental revenue from these initiatives, targeting overall revenue of ₹400 crore by FY27, while implementing cost optimization through a 10.8 MW solar plant expected to save ₹9 crore annually.
10
Feb 26
Amanta Healthcare Limited Announces Changes in Senior Management Personnel
Amanta Healthcare Limited announced changes in its senior management personnel effective February 10, 2026, with Board approval for the inclusion of Shri Urmil Oza as Senior Management Personnel and removal of Shri Shailesh Shah. Urmil Oza, Vice President - Engineering, brings 30 years of experience including 26 years with the company, specializing in production engineering, utility management, and regulatory compliance. The company has notified BSE and NSE about these changes in compliance with SEBI regulations.
02
Feb 26
Amanta Healthcare Opens Special Window for Transfer and Dematerialisation of Physical Securities
Amanta Healthcare Limited has opened a special window for transfer and dematerialisation of physical securities from February 05, 2026 to February 04, 2027, following SEBI Circular dated January 30, 2026. The one-year window allows investors to re-lodge transfer deeds for securities sold or purchased prior to April 01, 2019 that were previously rejected due to document deficiencies. Investors can submit complete documentation to MUFG Intime India Private Limited, the company's Registrar and Transfer Agent based in Ahmedabad.
02
Jan 26
Amanta Healthcare Corrects Solar Power Plant Capacity to 10.8 MWp in Revised Agreement
Amanta Healthcare Limited issued a correction regarding its solar power plant project with Zodiac Energy Limited, rectifying the capacity from an erroneously reported 10.8 KWp to the correct 10.8 MWp. The company re-executed the agreement on January 02, 2026, maintaining all other terms and conditions while confirming regulatory compliance under SEBI regulations.
14
Nov 25
Amanta Healthcare Allocates Rs 3,030 Crore from IPO Proceeds for Expansion
Amanta Healthcare Limited has used Rs 3,030.02 lakhs from its IPO proceeds for the quarter ending September 30, 2025. The funds were primarily used for capital expenditure at its Gujarat facility, including manufacturing equipment and civil construction. The company still has Rs 9,569.98 lakhs available for further planned expansions. Amanta plans to commence a SteriPort Manufacturing Line in January 2026 and an SVP Manufacturing Line in January 2027, both located in Hariyala, Kheda, Gujarat. For Q2 FY2026, the company reported a total income from operations of Rs 7,095.80 lakhs and a net profit after tax of Rs 120.76 lakhs.
12
Nov 25
Amanta Healthcare Reports Fund Utilization Deviation and Q2 FY2026 Financial Results
Amanta Healthcare Limited disclosed a deviation in IPO fund utilization due to GST payment changes, adjusting issue expenses and reducing general corporate purpose expenses. The company's Q2 FY2026 results show revenue growth to Rs. 7,088.73 lakhs, but a decrease in net profit to Rs. 120.75 lakhs compared to Q2 FY2025. Half-year performance improved with revenue at Rs. 13,619.44 lakhs and net profit at Rs. 471.47 lakhs. Balance sheet highlights include increased total assets of Rs. 48,831.55 lakhs and improved cash position of Rs. 9,196.41 lakhs as of September 30, 2025.
12
Nov 25
Amanta Healthcare Reports Q2 Profit, Completes IPO Listing
Amanta Healthcare Limited reported Q2 FY2026 results with total income of Rs. 7,095.80 lakhs and net profit of Rs. 207.80 lakhs. For H1 FY2026, total income was Rs. 13,850.45 lakhs with net profit of Rs. 185.50 lakhs. The company completed its IPO, issuing 10 million shares at Rs. 126 each, raising Rs. 12,600 lakhs. Listing occurred on September 9, 2025, on BSE and NSE. IPO proceeds are allocated for new manufacturing lines and corporate purposes, with Rs. 3,030.02 lakhs utilized so far. PriceWaterhouseCoopers provided an unmodified review opinion on the financial results.
Amanta Healthcare
108.
07
+
2.
26
(+
2.
14
%)
1 Year Returns:
-23.76%
Industry Peers
Sun Pharmaceutical
1,693.60
(-
2.
02
%)
Divis Laboratories
5,856.50
(-
0.
85
%)
Torrent Pharmaceuticals
3,987.20
(-
3.
02
%)
Lupin
2,274.50
(-
0.
02
%)
Dr Reddys Laboratories
1,217.30
(+
0.
64
%)
Cipla
1,192.40
(-
0.
29
%)
Zydus Life Science
864.25
(+
0.
12
%)
Mankind Pharma
1,998.50
(-
0.
14
%)
Aurobindo Pharma
1,333.70
(-
0.
63
%)
Alkem Laboratories
5,258.00
(+
0.
26
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO